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Abstract
Background: Gene disruption in mouse embryonic stem cells or zygotes is a
conventional genetics approach to identify gene function in vivo. However, because
different gene disruption strategies use different mechanisms to disrupt genes, the
strategies can result in diverse phenotypes in the resulting mouse model. To
determine whether different gene disruption strategies affect the phenotype of
resulting mutant mice, we characterized Rhbdf1 mouse mutant strains generated by
three commonly used strategies—definitive-null, targeted knockout (KO)-first, and
CRISPR/Cas9.
Results: We find that Rhbdf1 responds differently to distinct KO strategies, for
example, by skipping exons and reinitiating translation to potentially yield gain-of-
function alleles rather than the expected null or severe hypomorphic alleles. Our
analysis also revealed that at least 4% of mice generated using the KO-first strategy
show conflicting phenotypes.
Conclusions: Exon skipping is a widespread phenomenon occurring across the
genome. These findings have significant implications for the application of genome
editing in both basic research and clinical practice.
Keywords: Definitive-null, Knockout-first, CRISPR/Cas9, Gene disruption, Exon
skipping, Gene editing, And RHBDF1
Background
Mice are closely related, genetically, to humans, and hence mice have been chosen as a
model system to decipher the function of ~ 20,000 protein-coding genes to gain in-
sights into human biology and disease. For large-scale mouse mutagenesis efforts, gene
targeting by homologous recombination in mouse embryonic stem (ES) cells was an ef-
ficient and versatile technique. Gene targeting involved either a definitive-null design,
which deleted the entire genomic sequence of the target gene, or a targeted knockout
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(KO)-first design, which offered several advantages, including a gene disruption and a
reporter-tagged mutation, and furthermore, permitted analysis of gene function in a
tissue-specific or temporal manner. Recently, the use of CRISPR/Cas9 to disrupt genes
directly in zygotes has superseded both the definitive-null and KO-first strategies. To
determine whether different gene-targeting strategies affect the phenotype of homozy-
gous mutant mice, we systematically characterize Rhbdf1 mutant mice generated by
these three KO strategies—definitive-null, targeted KO-first, and CRISPR/Cas9. The
Rhbdf1 gene encodes RHBDF1 and has been implicated as playing a key role in growth
and development [1], inflammation [2], and cancer [3–5].
Definitive-null and targeted KO-first strategies are powerful high-throughput ap-
proaches that can be used for large-scale gene targeting in ES cells to study thousands
of mammalian protein-coding genes to better understand human biology and disease
[6–8]. In the use of the definitive-null strategy, bacterial artificial chromosome (BAC)-
based targeting vectors replace the entire genomic sequence of the target gene
(Additional file 1: Figure S1a), thereby generating a null allele. In contrast, the targeted
KO-first approach [9, 10], a strategy that includes alternative steps that can be chosen
based on the desired result, is highly versatile, as it enables the analysis of gene function
in a tissue-specific or temporal manner. The KO-first allele is created through targeted
delivery of a cassette that includes a mouse En2 splice site, a β-galactosidase reporter, a
neomycin resistance gene, and a transcriptional termination SV40 polyadenylation se-
quence, into the intronic sequence. Transcription of the targeted gene is terminated by
the polyadenylation sequence before the entire gene sequence is transcribed, resulting
in truncated transcription of a nonfunctional reporter protein. Application of Cre
recombinase to a KO-first ES cell clone results in generation of a null allele (Add-
itional file 1: Figure S1b). Application of Flp recombinase to a KO-first ES cell
clone converts the KO-first allele into a conditional-ready (or simply a wildtype) al-
lele by removing the cassette flanked by the FRT sites (Additional file 1: Figure
S1c); subsequent application of Cre recombinase elegantly generates conditional al-
leles by deleting exon(s) that are flanked by loxP sites (Additional file 1: Figure
S1c). The “KO-first” alleles, by offering substantial flexibility with respect to either
gene disruption or target tissue expression and timing, are time-efficient. Despite
evidence suggesting that targeted KO-first alleles may result in hypomorphs [11],
to our knowledge there have been no reports indicating that use of the targeted
KO-first strategy has led to gain-of-function alleles that rescue the severe pheno-
type caused by the null alleles.
CRISPR/Cas9-mediated genome editing is currently the primary conventional ap-
proach for generating null alleles [12]. This method relies on the introduction of frame-
shift mutations via non-homologous end joining (NHEJ) in ES cells or zygotes to
trigger nonsense-mediated decay (NMD) of mRNA transcripts [13]. However, emerging
evidence suggests that these mutant alleles can reinitiate translation from a down-
stream start codon resulting in truncated proteins [14]. Recently, two separate studies
performed systematic analysis of CRISPR/Cas9-induced frameshift mutations in HAP1
cells and revealed that one third of the genes could generate truncated proteins either
by reinitiating translation or skipping the edited exon [15, 16]. Likewise, in zebrafish,
CRISPR/Cas9-mediated generation of KO alleles resulted in unpredicted mRNA tran-
scripts owing to exon skipping, nonsense-associated altered splicing, or use of cryptic
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splice sites [17]. Collectively, these studies highlight the limitations of CRISPR/Cas9-
mediated generation of null alleles.
Building on the aforementioned work in HAP1 cell lines and mutant zebrafish lines,
we comprehensively characterized Rhbdf1 mutant mouse strains generated by three dis-
tinct gene-targeting strategies—definitive-null, targeted KO-first, and CRISPR/Cas9—
using whole-exome sequencing (Exome-Seq), RNA sequencing (RNA-Seq), 5′-rapid
amplification of cDNA ends (RACE), and functional analysis of residual proteins. We
find that whereas definitive-null Rhbdf1 mutant mice (hereafter referred to as
Rhbdf1null/null) show growth retardation, brain and heart defects, and the death of the
majority of mice by postnatal day 14 (P14), targeted KO-first- and CRISPR/Cas9-engi-
neered Rhbdf1 mutant mice do not display growth retardation or any of the other path-
ologies observed in the Rhbdf1null/null mice, suggesting incomplete elimination of
RHBDF1 biological activity. Comprehensive analyses of all three Rhbdf1 mutant alleles
revealed the existence of functional N-terminally truncated RHBDF1 mutant proteins
capable of rescuing the multi-organ pathology observed in Rhbdf1null/null mice. Our
data suggest that because mutant transcripts are capable of generating functional trun-
cated proteins, a thorough post-genomic-DNA analysis of targeted KO-first- and CRIS
PR/Cas9-engineered alleles, and additional studies as well, is warranted to validate the
null alleles before phenotypic characterization of mutant mouse strains.
Results
Does the choice of gene-targeting strategy affect the phenotype?
In recent studies, two different groups each generated Rhbdf1 homozygous mutant
mice, and reported conflicting results regarding the phenotypes [1, 18]; Christova and
colleagues, using the definitive-null strategy, generated an Rhbdf1 loss-of-function mu-
tation in two different inbred mouse strains: C57BL/6J and 129S6. In both strains,
heterozygous-null mice were normal and indistinguishable from wildtype littermates,
whereas homozygous-null mice had low body weights and died at about 9 days
(C57BL/6J) and 6 weeks (129S6) after birth (Fig. 1a, see A1). In contrast, using the tar-
geted KO-first strategy, Li and colleagues reported that Rhbdf1 mutant mice generated
on a mixed genetic background—C57BL/6N and FVB—were healthy with no apparent
phenotypic or histological abnormalities, and proposed that RHBDF1 is not essential
for mouse development (Fig. 1a, see A3). Furthermore, Christova et al. (using both
C57BL/6J and 129S6 mice) and Li et al. both generated Rhbdf1:Rhbdf2 double mutant
mice, and the phenotypes differed considerably between the two studies. While
Christova et al. reported in utero lethality in the double mutants (Fig. 1a, see A2), Li
et al. observed perinatal lethality with an “eyelids open at birth” phenotype and heart
valve defects (Fig. 1a, see A4).
It seems unlikely that there is a modifier in the B6 congenic E2a-Cre strain [B6.FVB-
TgEIIa-cre; Stock No: 003724] strain that could account for the difference in the
phenotype observed in the single and double mutant mice generated on the C57BL/6J
background by Christova et al. It seems more likely, rather, that the differences in the
phenotypes could be due to effects of the different gene-targeting strategies employed
(Fig. 1a) by the two studies to generate Rhbdf1 KO mice. Notably, both the transcrip-
tion start site and the start codon remain unaltered by the targeted KO-first strategy.
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To address the underlying cause of discrepancy, we generated (a) Rhbdf1 KO mice
using the definitive-null design, which results in alleles that delete the entire protein-
coding sequence of the target gene (Fig. 1b, see A5), and (b) Rhbdf1 KO mice using
Fig. 1 Analysis of Rhbdf1-deficient mice suggests that the targeting strategy might affect the phenotype of
homozygous mutant mice. a Schematic representation of exons (filled boxes) and introns (lines) in the
Rhbdf1 gene. Previous studies have produced conflicting results regarding the consequences of Rhbdf1
inactivation in mice. Christova et al. reported that Rhbdf1−/− mice generated using the VelociGene
definitive-null gene KO strategy suffer from multi-organ pathologies and die within ~ 6 weeks (A1) and that
the Rhbdf1−/− Rhbdf2−/− (A2) double KO mice, generated using A1 Rhbdf1−/− mice, died prenatally with
phenotypes that were significantly more severe. In contrast, Li et al. reported that Rhbdf1−/− homozygous
mutant mice generated with a targeted KO-first allele showed no evidence of pathological phenotypes
(A3). Moreover, Rhbdf1−/− Rhbdf2−/− double mutant mice, generated using A3 Rhbdf1−/− mice, exhibited less
severe disease phenotypes, such as heart valve defects and an “open eyelids at birth” phenotype (A4). b We
hypothesized that the targeted KO-first allele (A3), but not the definitive-null allele, generates an N-
terminally truncated RHBDF1 protein product from the mutant mRNA that is not degraded by the NMD
mechanism, to rescue the overt phenotype observed in RHBDF1-deficient mice (A1). To test our hypothesis,
we independently generated Rhbdf1 homozygous mutant mice using two different strategies: (1) delete
complete coding sequence (A5) and (2) delete exon(s) containing the start codon (A7). We postulated that
whereas the A5 allele would be analogous to the A1 definitive-null allele, the A7 allele would generate a
functional truncated mutant RHBDF1 protein, analogous to the targeted KO-first mutant allele A3, rescuing
the multi-organ pathology of RHBDF1-deficient mice (A1). c Table indicating the phenotypes of previously
generated Rhbdf1 single mutant and Rhbdf1:Rhbdf2 double mutant mice
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CRISPR/Cas9-mediated gene editing (Fig. 1b, see A7), which results in alleles lacking
the exon(s) with the translation initiation site ATG. We hypothesized that the mutant
transcripts generated from the targeted KO-first or CRISPR/Cas9 alleles reinitiate tran-
scription and translation in unexpected ways to rescue the more severe phenotype de-
scribed by Christova et al. We sought to test our hypothesis by systematically
characterizing the Rhbdf1 single mutant mice and Rhbdf1:Rhbdf2 double mutant mice
generated in the present study, comparing the phenotypes with those reported in previ-
ously published studies (Fig. 1c).
Complete loss of exons in Rhbdf1 (A5 allele) results in growth retardation, brain
hemorrhage, and cardiac hypertrophy
To explore the function of RHBDF1 in vivo, we generated Rhbdf1 homozygous-null
(Rhbdf1−/−) mice from heterozygotes with the A5 allele and validated Rhbdf1 gene dis-
ruption by whole-exome sequencing (Exome-Seq, Fig. 2a) and polymerase chain reac-
tion (PCR; Fig. 2b). Exome-Seq validated loss of exons 3 through 18, leading to
deletion of almost all of the cytosolic N-terminus domain and all of the transmembrane
domains. Filial crosses of heterozygotes resulted in near-Mendelian ratios, suggesting
no embryonic lethality due to RHBDF1 deficiency. Moreover, all Rhbdf1−/− newborns
had a milk spot, and as neonates showed no gross deformities or malformations of
major organs, except for growth retardation when compared with Rhbdf1+/− littermates
(Fig. 2c, left). The majority of Rhbdf1−/− mice were found dead by P14, while the few
remaining Rhbdf1−/− neonates survived only to 3 to 4 weeks (Fig. 2d). These survivors
appeared severely dehydrated and lethargic, and both female and male Rhbdf1−/− survi-
vors exhibited significantly lower body weight compared with Rhbdf1+/− littermates
(Fig. 2e).
In addition to the generalized growth deficiency of Rhbdf1−/− survivors, specific ab-
normalities were observed in the brain and heart. Gross examination of whole brains
from P21 Rhbdf1−/− mice revealed hemorrhages, and histological examination of
Rhbdf1−/− brain sections confirmed several hemorrhages throughout the brain. These
were evident in the ventricles adjacent to the brain stem, hippocampus, and hypothal-
amus (Fig. 2f), without significant inflammation. Additionally, P21 Rhbdf1−/− mice dis-
played left atrial enlargement with left ventricular hypertrophy, which is reflected in the
higher heart weight/body weight ratio in these homozygous mice compared to hetero-
zygotes (Fig. 2g). Histological sections of the hearts revealed perivascular and interstitial
fibrosis in the left ventricle and interventricular septum (Fig. 2h). In agreement with
these data, heart-to-body-weight ratios revealed significant cardiac hypertrophy in the
Rhbdf1−/− animals. In contrast, no lesions were detected in hearts from Rhbdf1+/− mice
aged up to 1 year. Our findings in the present study—that Rhbdf1−/− mice on a pure in-
bred C57BL/6N strain background have significantly lower body weight compared with
heterozygous-null mice, with most Rhbdf1−/− mice dying postnatally from brain hemor-
rhages and cardiac fibrosis—are similar in many ways to those of the Christova et al.
study, but very different from those of Li et al. Notably, Christova et al. generated mice
on two different strain backgrounds—C57BL/6J and 129S6/SvEvTac—and showed that
whereas homozygotes on each background showed severe weight loss, brain
hemorrhage, and cardiac infarction, and died by ~ 6 weeks, heterozygotes on each
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background were normal. Collectively, these data suggest an essential role for RHBDF1
during postnatal development, and hereafter, the definitive-null Rhbdf1 homozygous-
null mice are referred to as Rhbdf1null/null mice.
Because the Rhbdf1 and Rhbdf2 genes have significant homology (~ 80%) in their se-
quences, we sought to address whether the phenotype of Rhbdf1:Rhbdf2 double KO
mice is more severe than that of Rhbdf1null mice; i.e., embryonic or perinatal lethality.
Fig. 2 Complete deletion of exons in Rhbdf1 results in growth retardation, brain hemorrhage, and cardiac
hypertrophy (A5). a Exome-Seq showing loss of exons 2 through 18 in Rhbdf1−/− homozygous mutant mice
generated using the definitive-null strategy. The red rectangle shows the exons lost in the mutant mice. b
PCR of tail genomic DNA with all four primers shows that wildtype mice have one wildtype band (268-bp
PCR product), heterozygous-null mice carry a wildtype band (268 bp) and a mutant band (546 bp), and
homozygous-null mice carry one mutant band (546 bp). NTC, no template control. New England Biolabs 1
kb DNA Ladder was used as a molecular marker. Samples were run in duplicate. c Images of representative
postnatal day 28 Rhbdf1−/− (left) and Rhbdf1+/− (right) male littermates. d Kaplan–Meier survival analyses
showing that the lifespan of Rhbdf1−/− homozygous-null female (left panel) and male (right panel) mice is
significantly shorter than that of heterozygous-null littermate controls. e Body weights of Rhbdf1−/− female
(n = 4) and male (n = 3) mice compared with those of Rhbdf1+/− littermates (n = 3 for each sex) on postnatal
day 21. Data represent mean ± S.D.; ***p < 0.001. f Brain hemorrhaging in Rhbdf1−/− mice. Upper left panel:
multifocal hemorrhages (arrows) were observed in Rhbdf1−/− mice. All other panels: H&E-stained coronal
sections of postnatal day 21 Rhbdf1−/− brain showing prominent hemorrhages in the brain stem,
hippocampus, and hypothalamus. g Enlarged hearts in both female (left panel) and male (right panel)
Rhbdf1−/− mice. Enlarged hearts were observed in pups older than 3 weeks of age. When we measured
heart and body weights of Rhbdf1−/− (n = 3 females; n = 4 males) and Rhbdf1+/− (n = 4 females; n = 5 males)
littermates at postnatal day 21, the heart-to-body-weight ratio (HW/BW) was significantly higher Rhbdf1−/−
mice relative to Rhbdf1+/− littermates. Data represent mean ± S.D.; *p < 0.05, ***p < 0.001. h Cardiac
complications in Rhbdf1−/− mice on postnatal day 21. Masson’s trichrome staining of heart sections from a
3-week-old Rhbdf1−/− mouse showing interventricular septum and left ventricular fibrosis. Notably, both
perivascular and interstitial fibrosis were observed in Rhbdf1−/− mice
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Notably, Rhbdf2−/− mice are viable and fertile and do not display growth retardation or
brain and heart defects [19–21]. Interestingly, in contrast to the viability of Rhbdf1null/-
null embryos, the combined loss of Rhbdf1 and Rhbdf2 resulted in subviability. Of 64
live births from Rhbdf1+/null Rhbdf2−/− parents, there were four pups born that were
homozygous-null for both genes (Rhbdf1null/null Rhbdf2−/−) (Additional file 1: Figure
S2a), suggesting subviability due to deficiency of both RHBDF1 and RHBDF2, and
suggesting functional redundancy between RHBDF1 and RHBDF2 during embryonic
development. Moreover, histopathological analysis of Rhbdf1null/null Rhbdf2−/− mice re-
vealed an “eyelids open at birth” phenotype (Additional file 1: Figure S2b and S2c), sug-
gestive of deficiencies in epidermal growth factor receptor (EGFR) signaling pathways
[22, 23]. These findings—that the majority of Rhbdf1null/null Rhbdf2−/− mice die in
utero—are similar to those of the study of Christova et al., who found that Rhbdf1:
Rhbdf2 double KO mice on either the C57BL/6J or the 129S6/SvEvTac backgrounds re-
sult in embryonic lethality.
CRISPR/Cas9-mediated deletion of exons 2 and 3 in Rhbdf1 results in viable and fertile
homozygous mutants with the A7 allele
We decided to investigate whether deletion of Rhbdf1 exons 2 and 3, which contain the
translation initiation codon, rather than deletion of the entire protein-coding sequence
of the target gene (as in the A5 allele), would result in mice that mimic Rhbdf1null/null
mice (Fig. 2) or mice that exhibit an altered phenotype owing to creation of an N-
terminally truncated abnormal protein product. We used CRISPR/Cas9 to generate this
Rhbdf1 mutant allele (A7), which excised exons 2 and 3 by the NHEJ repair pathway
(Fig. 3a and Additional file 1: Figure S3). Mutant mice that are homozygous for this al-
lele are hereafter referred to as viable (Rhbdf1v/v) mice. We observed that whereas
heterozygous-viable (Rhbdf1+/v) mice have one wildtype band (1300 bp PCR product)
and one mutant band (728 bp), homozygous-viable (Rhbdf1v/v) mice have only the mu-
tant band (728 bp) (Fig. 3b, left). The deletion of DNA sequence was further validated
by Sanger’s sequencing (Fig. 3b, right). None of the Rhbdf1v/v pups showed gross de-
formities or malformations of major organs in contrast to the majority of Rhbdf1null/null
mice, which were found dead by P14 (Fig. 2). Rhbdf1v/v mice were healthy, viable, and
fertile (Fig. 3c–e). Additionally, no specific abnormalities were observed in the brain,
heart, kidney, spleen, skin, or liver by histological examination (Fig. 3f, g and Add-
itional file 1: Figure S4a). This is also reflected in the normal heart weight/body weight
ratio in Rhbdf1+/v and Rhbdf1v/v mice (Fig. 3h), compared with that of Rhbdf1null/null
mice. These findings are similar in many ways to those of the Li et al. study, who found
that the Rhbdf1 mutant mice they generated were indistinguishable from their litter-
mate controls [18].
Exome-Seq of Rhbdf1v/v mice validated an in-frame 572-bp deletion in the Rhbdf1
gene, resulting in loss of exons 2 and 3 (Fig. 3i). To examine whether this deletion pro-
duces an alternative Rhbdf1 transcript, we performed RNA-Seq on RNA derived from
spleens of Rhbdf1v/v mice, which showed the Rhbdf1v/v transcript lacked exons 2 and 3,
but contained all of the other exons (1, and 4 through 18) (Fig. 3j). Because the normal
translation initiation site (ATG) in exon 3 is missing, we predicted that the Rhbdf1v/v
transcript could produce a protein variant or a truncated RHBDF1 protein by utilizing
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Fig. 3 (See legend on next page.)
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the next in-frame translation initiation site in exon 4. Notably, Rhbdf1 transcript vari-
ants X2, X3, and X4 all lack exons 2 and 3 [24], but generate an alternative mRNA
transcript, which is likely to result in a 706-amino acid product utilizing the next in-
frame ATG in exon 4 (Fig. 3k and Additional file 1: Figure S4b).
To determine whether the Rhbdf1v/v truncated protein is functional and
whether it could rescue RHBDF1 deficiency, we performed in vitro stimulated se-
cretion assays in primary mouse embryonic fibroblasts (MEFs). Previous studies
have shown that RHBDF1 regulates protein kinase C activator phorbol ester
(PMA)-mediated stimulated secretion of epidermal growth factor receptor (EGFR)
ligands, including amphiregulin (AREG) [20]. Here, using PMA-induced stimu-
lated secretion assays in Rhbdf1+/+ and Rhbdf1−/− primary MEFs (A5 allele), we
found that, upon stimulation with 100 nM PMA, Rhbdf1+/+ MEFs showed a sig-
nificant increase in AREG secretion compared with Rhbdf1−/− MEFs, indicating
that RHBDF1 deficiency suppresses AREG secretion (Additional file 1: FigureS5).
Hence, we asked whether the variant proteins can rescue the “stimulated secre-
tion of AREG” phenotype, by transiently transfecting Rhbdf1v/v-expressing vector
(Fig. 3l) in Rhbdf1−/− primary MEFs, and measuring AREG levels following stimu-
lation with PMA (Fig. 3m). Stimulation with PMA significantly increased AREG
levels in Rhbdf1v/v-transfected MEFs compared with empty vector-transfected
MEFs, suggesting that Rhbdf1v/v is capable of inducing AREG secretion and
thereby rescuing the phenotype.
(See figure on previous page.)
Fig. 3 Deletion of exons 2 and 3 in Rhbdf1 results in viable and healthy mice (A7). a CRISPR/Cas9-mediated
deletion of exons 2 and 3 resulted in an in-frame 572-bp deletion in the Rhbdf1 gene (hereafter referred to
as viable mice, Rhbdf1v/v). b The schematic shows the deleted exons and the PCR strategy to amplify the
region. PCR of genomic DNA with primers flanking exons 2 and 3 shows that wildtype mice have one
wildtype band (1300-bp PCR product), heterozygous mice carry a wildtype band (1300 bp) and a mutant
band (728 bp), and homozygous-null mice carry one mutant band (728 bp). Samples were run in duplicate.
DNA sequencing further validated an in-frame 572-bp deletion in genomic DNA (right). Also, see
Additional file 1: Figure S4. c Images of representative postnatal day 15 Rhbdf1−/− mice (left) and Rhbdf1v/v
mice (right). d Kaplan–Meier survival analyses showing that the lifespan of Rhbdf1v/v mice (A7) is
significantly longer than that of Rhbdf1−/− mice (A5). e Body weights of Rhbdf1v/v mice compared with
those of Rhbdf1−/− mice on postnatal day 21. Data represent mean ± S.D.; ***p < 0.001. f H&E-stained
coronal sections of a postnatal day 21 Rhbdf1−/− brain showing prominent hemorrhages in the brain; in
contrast, there was no evidence of brain hemorrhaging in Rhbdf1v/v mice. g Cardiac abnormalities were
observed in Rhbdf1−/− mice but not in Rhbdf1v/v mice (right). The black rectangle illustrates cardiac fibrosis
in Rhbdf1−/− mice (left). h Also, heart weight was significantly lower in Rhbdf1v/v mice than in Rhbdf1−/−
mice. Data represent mean ± S.D.; ***p < 0.001. i Exome-Seq showing loss of exons 2 and 3 in Rhbdf1v/v
mutant mice and not in Rhbdf1+/+ mice. The red rectangle shows the exons lost in the mutant mice. j RNA
sequencing analysis of spleens isolated from Rhbdf1v/v mice indicating that CRISPR/Cas9-mediated deletion
of exons 2 and 3 does not result in nonsense-mediated decay of mutant Rhbdf1v/v mRNA. Note the boxed
region preceding the lost exons 2 and 3 indicates the presence of alternative transcripts. k Although the
translation initiation site in exon 2 is deleted in Rhbdf1v/v mice, sequence analysis of Rhbdf1v/v cDNA
revealed that the next in-frame translation initiation site (ATG) was in exon 4, which could potentially result
in an N-terminally truncated protein to rescue the severe pathology of Rhbdf1−/− mice (A5). l Double
digests of C-terminal Myc-DDK-tagged Rhbdf1viable and Rhbdf1non-AUG vectors using EcoRI-HF and NotI-HF
restriction enzymes. m Rescue experiments in Rhbdf1−/− MEFs. RHBDF1 deficiency suppresses stimulated
secretion of AREG in primary MEFs (see Additional file 1: Figure S5); hence, we performed rescue
experiments to restore stimulated AREG secretion in Rhbdf1−/− MEFs (A5); Rhbdf1−/− MEFs were transiently
transfected with 2 μg of either a full-length vector, or a Rhbdf1viable vector, or a Rhbdf1non-AUG vector, using
Lipofectamine LTX. Forty-eight hours post-transfection, cells were stimulated overnight with either DMSO or
100 nM PMA, and cell culture supernatants were analyzed using a mouse AREG ELISA kit. Data represent
mean ± S.D.; (a) significantly different from a full-length vector-transfected and DMSO-stimulated cells; (b)
significantly different from a full-length vector-transfected and PMA-stimulated cells
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Because a majority of double mutant Rhbdf1null/null Rhbdf2−/− mice die in utero, we
asked whether the Rhbdf1v/v mutation can rescue the subviability of Rhbdf1null/null
Rhbdf2−/− mice, by generating Rhbdf1v/v Rhbdf2−/− mice. In contrast to the subviability
of Rhbdf1null/null Rhbdf2−/− mice, Rhbdf1v/v Rhbdf2−/− mice were viable, healthy, and
fertile (Additional file 1: Figure S6a). Nevertheless, Rhbdf1v/v Rhbdf2−/− mice exhibited
wavy-coated hair and “eyelids open at birth” phenotypes (Additional file 1: Figure S6b
and S6c), indicative of alterations in epidermal growth factor receptor (EGFR) signaling
pathways. Histopathological analysis revealed no evidence of heart or brain abnormal-
ities (Additional file 1: Figure S6d).
Literature suggests that, in addition to the canonical AUG start codons, non-AUG
start codons are capable of initiating translation [25–28]. Notably, Rhbdf1 protein-
coding transcript 206 [24] utilizes a non-AUG start codon, CGC (arginine, R), rather
than AUG (methionine, M) (Additional file 1: Figure S7a). We next sought to examine
whether mRNA translation initiation from non-AUG start codons can generate func-
tional protein-coding transcripts that rescue the phenotype. Since there are no vali-
dated RHBDF1-specific antibodies, we obtained C-terminal Myc-DDK tagged
expression vector for the non-AUG mutant transcript, and heterologously expressed
them in 293T cells. Western blotting revealed that non-AUG vector, based on their
molecular masses, generated expected size bands (~ 30 kDa) while transfection with an
empty tagged vector did not produce any bands (Additional file 1: Figure S7b). Add-
itionally, when the non-AUG-expressing vector (Fig. 3l) was transfected into Rhbdf1−/−
primary MEFs, it induced significant AREG secretion (Fig. 3m). This result is similar to
the Rhbdf1v/v transcript in transfected MEFs, suggesting that the non-AUG start codon
CGC is capable of generating a functional protein-coding transcript. Thus, we conclude
that mutant Rhbdf1v/v protein products rescue the severe phenotype observed in mice
deficient in RHBDF1 (both Christova et al. and our Rhbdf1null/null mice), because of the
use of alternative AUG and non-AUG start codons that nevertheless give rise to mostly
functional proteins.
Targeted KO-first allele Rhbdf1 homozygous mutants (A3) express truncated protein
isoforms that rescue the pathology of Rhbdf1null/null mice
Additional crosses of mice carrying the Rhbdf1 KO-first allele to Cre transgenic mice
resulted in excision of exons 4–11 flanked by the loxP sites (Fig. 4a). These homozy-
gous mutant mice were generated by Li et al. and are hereafter referred to as viable 2
mice (Rhbdf1v2/v2). Exome-Seq of these mice validated deletion of exons 4–11 in the
Rhbdf1 gene (Fig. 4b). RT-PCR (Fig. 4c and Additional file 1: Figure S8) and RNA-Seq
(Fig. 4d) confirmed that exons 4 through 11 are missing in the transcript, while exons
12 through 18 remain intact. The structure of the Rhbdf1v2/v2 transcript suggests that
exons 3 and 12 might be spliced together. To test this, we performed RT-PCR on the
Rhbdf1v2/v2 transcript using probes in exon 3 and in exon 12. Instead of an expected
209-bp product suggesting that exons 3 and 12 are joined together, we detected a 324-
bp PCR product, indicating insertion of a short 115-bp DNA fragment. Sanger sequen-
cing of this product revealed that the Rhbdf1v2/v2 mRNA retained the En2 splice ac-
ceptor sequence (Additional file 1: Figure S8b,c) from the cassette (Additional file 1:
Figure S8d). Nonetheless, the resultant Rhbdf1v2/v2 mutant transcript retains an in-
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frame termination codon (TAA), which will result in a 10.8-kDa short truncated pro-
tein product (Additional file 1: Figure S8e).
We next sought to explore whether the conditional Rhbdf1v2/v2 mutation leads to
additional truncated proteins via the use of an alternative promoter usage or via exon
skipping to reinitiate translation [15, 29, 30]. To evaluate the 5′ ends of mutant
Rhbdf1v2/v2 mRNA transcripts, we performed 5′ RACE on first-strand cDNA using a
gene-specific exon 16–17 fusion primer, based on the RT-PCR evidence for the pres-
ence of a 211-bp product (Fig. 4c). The resulting RACE products were characterized by
Sanger sequencing following agarose gel electrophoresis and In-Fusion cloning. Se-
quence analyses of identified clones revealed the existence of an alternative exon 1,
199 bp upstream of the conventional exon 1 (Additional file 1: Figure S9 and S10).
Interestingly, we found evidence for two potential transcripts that utilize this alternative
exon 1 (Additional file 1: Figure S11 and S12) that could generate N-terminally trun-
cated Rhbdf1v2/v2 proteins by alternative splicing (Fig. 4e). We also obtained C-terminal
Myc-DDK-tagged expression vectors for variant 1 and 2 mutant transcripts, and heter-
ologously expressed them in 293T cells (Additional file 1: Figure S13). Western blotting
revealed that both variants (1 and 2), based on their molecular masses, generated ex-
pected size bands (~ 32-kDa and ~ 29-kDa) while transfection with an empty tagged
vector did not produce any bands (Fig. 4f).
Lastly, using PMA-induced stimulated secretion assays, we observed that, first, in
both Rhbdf1+/+ and Rhbdf1−/− MEFs, transfection alone with either variant protein 1 or
(See figure on previous page.)
Fig. 4 Targeted KO-first targeting strategy in Rhbdf1 (A3) generates novel transcripts and N-terminally
truncated functional proteins. a Schematic of the strategy used by Li et al. for generation of Rhbdf1−/−
homozygous mutant mice; the Rhbdf1 KO-first allele was crossed to Cre transgenic mice to excise the
floxed gene segment (exons 4–11), generating Rhbdf1−/− homozygous mutant mice (hereafter referred as
viable2 mice, Rhbdf1v2/v2 mice). b Whole-exome sequencing of spleen tissue from Rhbdf1v2/v2 mice showing
loss of exons 4 through 11 in Rhbdf1v2/v2 mutant mice. c RT-PCR on spleens from Rhbdf1+/+ and Rhbdf1v2/v2
mutant mice using primers to amplify exons 6 through 8, exons 7 through 10, and exons 16 and 17. Exons
4–11 are deleted in Rhbdf1v2/v2 mutant mice; hence, no amplicons were generated using either exon 6
forward and exon 8 reverse, or exon 7 forward and exon 10 reverse, primers. However, exon 16 forward
and exon 17 reverse primers generated a 211-bp product. d RNA-Seq analysis of spleens from Rhbdf1v2/v2
mutant mice indicating loss of exons 4 through 11; however, there is strong evidence for mutant mRNA, as
indicated by the presence of the rest of the transcript, which encodes exons 12 through 18 and is not
degraded by the nonsense-mediated decay mechanism. e Schematic representation of exons and introns
in the Rhbdf1v2/v2 mutant allele. 5′ RACE using a gene-specific exon 16–17 fusion primer (GSP) was used to
obtain 5′ ends of the Rhbdf1v2/v2 mutant mRNA. We identified several novel mutant mRNAs with different
translation initiation sites that could potentially generate N-terminally truncated RHBDF1 mutant proteins.
See supplemental figures for variant protein and 5′ UTR sequences. Alternative exons are indicated as red
boxes; predicted translation initiation sites are indicated by “START,” and termination codons are indicated
by “STOP.” f C-terminal Myc-DDK-tagged Rhbdf1v2/v2 variant protein 1 (lanes 1, 2) or variant protein 2 (lanes
3,4), or empty vector (lanes 5, 6) were transiently expressed in 293T cells, and cell lysates were analyzed
using western blotting with FLAG-specific antibody. After visualization of blots with a G:Box
chemiluminescent imaging system, blots were washed, blocked in 5% nonfat dry milk, and re-probed with
anti-actin antibody. g Rescue of phenotype in Rhbdf1−/− MEFs. Rhbdf1+/+ (top) and Rhbdf1−/− (bottom) MEFs
were transiently transfected with 2 μg of either variant 1 or variant 2 vectors, or an empty vector, using
Lipofectamine LTX. Forty-eight hours post-transfection, cells were stimulated overnight with either DMSO or
100 nM PMA, and cell culture supernatants were analyzed using a mouse AREG ELISA kit. Data represent
mean ± S.D.; *p < 0.05, ***p < 0.001. h Comparison of phenotypes of previously generated Rhbdf1 single
mutant and Rhbdf1:Rhbdf2 double mutant mice with those of mice generated in the present study. The
viability of Rhbdf1v/v, Rhbdf1v2/v2, and Rhbdf1v/v Rhbdf2−/− double mutant mice demonstrates that the
incomplete coding sequences not degraded by NMD have functional significance and, moreover, that
targeted KO-first conditional mutagenesis (A3) or CRISPR/Cas9-mediated deletion of exon(s) (A7), in contrast
to complete deletion of exons (A1 and A5), can yield gain-of-function alleles
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2 significantly increased AREG secretion compared with that of the empty vector
(Fig. 4g). Second, stimulation with PMA further increased AREG levels in both variant
protein 1- or 2-transfected MEFs compared with empty vector transfected MEFs, sug-
gesting that both of the N-terminally truncated RHBDF1 variant proteins are capable
of inducing AREG secretion and thereby rescuing the phenotype (Fig. 4g). Collectively,
these data suggest that the lack of spontaneous pathological phenotypes in the
Rhbdf1v2/v2 mutant mice could be explained by the presence of residual mRNA tran-
scripts and protein isoforms that can prevent the more severe phenotype observed in
the Rhbdf1null/null mice, and that the Rhbdf1v2/v2 mice with the targeted KO-first allele
(A3) are not homozygous-null (Fig. 4h).
Identifying unexpected translation by analyzing incomplete protein-coding sequences
(CDS) evading nonsense-mediated decay
We next investigated whether we could find mouse and human protein-coding genes
that are likely predisposed to targeted KO-first- and CRISPR/Cas9-mediated illegitim-
ate or unexpected transcription and translation. Several factors, including exon skip-
ping, alternative promoter usage, and translation reinitiation at AUG and at non-AUG
start codons, could result in abnormal phenotypes. Identifying mouse and human
protein-coding genes that express incomplete coding transcripts (Additional file 2:
Table S1, Additional file 3: Table S2, Additional file 4: Table S3, Additional file 5: Table
S5) that are not subjected to NMD could help identify genes resilient to targeted KO-
first or frameshift indels. We found that at least 35% of mouse and 45% of human
protein-coding genes generate protein-coding transcripts that are not eliminated by
NMD (Fig. 5a). For instance, the Ensembl site lists nine transcripts (Rhbdf1-201
through Rhbdf1-209) for mouse Rhbdf1 (Fig. 5b). Of the four protein-coding Rhbdf1
transcripts (201, 206, 207, and 209), transcript 206 has a 5′ incomplete CDS and is
comprised of only exons 14 through 18. As such, this transcript is not likely to be de-
graded by NMD when alleles with targeting event 5′ of these exons are generated. In-
deed, our tests in the present study were focused on amplifying exons 15 through 18 in
the Rhdbf1v2/v2 allele (Fig. 4c). Additionally, 5′ RACE on first-strand Rhdbf1v/v and
Rhdbf1v2/v2 cDNA was performed using a gene-specific exon 16–17 fusion primer
(Fig. 4e). Importantly, targeted KO-first mutagenesis excised only exons 4 through 11,
leaving the exons in the Rhbdf1-206 transcript (14 to 18) untouched and thus not likely
to be subject to NMD.
BAZ2A is another example of a gene that was recently identified during systematic
characterization of frameshift KO mutations in HAP1 cells showing residual protein ex-
pression [15], that we could identify here based on the presence of incomplete CDS
(Fig. 5c). In Additional file 6: Table S5, we present additional examples of the genes
that retain residual protein expression/function upon CRISPR/Cas9-induced indels in
recent literature [14–17, 28–31] and that we validate as good candidates for unantici-
pated translation based on the incomplete CDS approach.
We also analyzed 3674 conditional-ready mouse strains [32] using the incomplete
CDS approach (Additional file 7: Table S6), and determined that at least 40% of
conditional-ready alleles can skew the mouse phenotype (Fig. 5d). For instance, the
Bbs5 conditional-ready allele is likely to generate a 5′ incomplete CDS and an N-
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terminally truncated protein despite missing exons 4 and 5, which are lost upon Cre-
mediated recombination (Fig. 5e).
In contrast to mutation of gene function via unsolicited translation following CRIS
PR/Cas9 or targeted KO-first gene targeting, can unsolicited translation be advanta-
geous for exploring the function of genes that are essential for survival? The Inter-
national Mouse Phenotyping Consortium (IMPC) systematically characterized 5000 KO
mouse strains and identified 410 lethal and 198 subviable genes [33]. Here, we analyzed
all of the lethal and subviable genes (Additional file 7: Table S6) and found that, upon
Cre recombination of conditional-ready alleles, nearly 40% of the lethal genes and 40%
of the subviable genes may result in unwanted translation and could potentially par-
tially rescue the mouse phenotype generated by a null mutation (Fig. 5f, g). We show
an example of the Anapc4 KO-first allele, in which the “lacZ reporter gene and neomy-
cin resistance gene” flanking the FRT recognition sites for FLP recombinase is placed
downstream of the second exon of the gene, and exon 3 is floxed by loxP sites for rec-
ognition by Cre recombinase. Flp recombinase removes the lacZ and neomycin cas-
sette, allowing reversal to a conditional-ready allele, while Cre recombinase deletes
exon 3, presumably generating null or conditional mutants (Fig. 5h). However, Anapc4
expresses incomplete protein-coding transcripts that lack exon 3 and that evade NMD
(Anapc4–209 and − 211), suggesting that these protein-coding transcripts could rescue
the phenotype and impact interpretation of the phenotype.
In accordance with our observations, emerging evidence from IMPC suggests that
several mouse strains generated using the targeted KO-first strategy exhibit conflicting
phenotypes: Dnmt3a (tm1a allele is homozygous viable; tm1b allele is homozygous
(See figure on previous page.)
Fig. 5 An “incomplete protein-coding CDS” approach to identifying on-target unintended transcription and
translation reinitiation. a Bioinformatics analyses of mouse (left) and human (right) protein-coding genes
with incomplete 5′ CDSs and incomplete 3′ CDSs reveals that ~ 50% of genes are potentially capable of
generating shorter transcripts and truncated proteins. The physiological significance of these incomplete
CDSs is unclear. However, it is yet to be determined whether gene-targeting strategies must be designed
to ensure the deletion of these incomplete, yet existing coding sequences that are not degraded by NMD.
Notably, a 3′ incomplete CDS is a protein-coding transcript which is missing the stop codon due to
incomplete evidence and a 5′ incomplete CDS is a protein-coding transcript which is missing the start
codon due to incomplete evidence. b The various transcripts of the mouse Rhbdf1 gene listed in Ensembl.
In this scenario, the definitive-null design, rather than either the targeted KO-first or CRISPR/Cas9-mediated
deletion of exon(s) containing the start codon, would prevent expression of a short 5′ incomplete Rhbdf1-
206 transcript. c CRISPR/Cas9-mediated frameshift mutation failed to induce complete deficiency of BAZ2A
in HAP1 cells; however, based on the presence of 5′ and 3′ incomplete CDSs (arrows), BAZ2A is likely to
generate truncated proteins upon targeted KO-first- or CRISPR/Cas9-induced on-target mutagenesis. d
Bioinformatics analyses of 3674 conditional-ready mouse strains identified that nearly 55% of conditional-
ready genes generate incomplete 5′ and 3′ CDSs. e Schematic of Bbs5 KO-first allele in which the “lacZ
reporter gene and neomycin resistance gene” flanking FRT recognition sites is placed downstream of the
third exon of the gene, and exons 4 and 5 are floxed by loxP sites. Following Cre-mediated recombination,
despite missing exons 4 and 5, Bbs5 5′ incomplete CDS 203 may generate an N-terminally truncated
protein. f Bioinformatics analyses of 410 lethal IMPC mouse strains identified that 166 essential genes that
generate incomplete 5′ and 3′ CDSs. g Schematic of Anapc4 KO-first allele in which the “lacZ reporter gene
and neomycin resistance gene” flanking the FRT recognition sites is placed downstream of the second exon
of the gene, and exon 3 is floxed by loxP sites. Although Cre recombination deletes exon 3, translation
reinitiation from incomplete CDSs 209 and 211 may rescue the lethal phenotype of Anapc4 homozygous-
null mice. h Analyses of 198 subviable IMPC mouse strains identified 81 genes generating incomplete 5′
and 3′ CDSs. i The targeted KO-first strategy in Dnmt3a results in conflicting phenotypes. Whereas the tm1a
KO-first allele generates homozygous-viable mice, the tm1b allele generates homozygous subviable mice
(top). Multiple protein-coding transcripts of Dnmt3a are shown. The Dnmt3a 207 protein-coding transcript
has incomplete 5′ and 3′ CDSs (arrow) (bottom)
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subviable) (Fig. 5i); Foxj3 (tm1a is homozygous viable; tm1b is homozygous lethal); and
Slc20a2 (tm1a is homozygous viable; tm1b is homozygous subviable), suggesting at
least partial rescue of gene function due to residual protein activity (Table 1 and Add-
itional file 8: Table S7). Notably, both the tm1a and tm1b mouse strains, KO-first and
post-Cre, respectively, should exhibit the same phenotype. Thus, we strongly believe
that, despite rigorous quality control of mutant mouse strains by the IMPC, additional
post-genomic-DNA characterization is required to ensure elimination of any residual
proteins of the targeted allele that might interfere with the phenotype. This is particu-
larly important when novel sequences are incorporated, such as those introduced by
targeted KO-first, making it extremely difficult to predict any novel mRNA transcripts
that may be generated.
Discussion
Several recent studies have reported that CRISPR/Cas9-mediated on-target gene KO
can produce novel unintended mRNA isoforms and truncated proteins that could at
least partially rescue activity of the targeted gene; Lalonde and colleagues found that
despite CRISPR/Cas9-induced on-target frameshift mutations in the phosphatase and
actin regulator 1 (PHACTR1) gene in human aortic endothelial cells, exon skipping re-
sults in novel functional PHACTR1 transcripts [29]. Also, in zebrafish lines, CRISPR/
Cas9-generated KOs display irregular phenotypes, owing to activation of cryptic splice
sites in mutant mRNA transcripts [17]. Similarly, to examine whether CRISPR/Cas9
mutations induce exon skipping to generate in-frame transcripts and truncated proteins
with functional outcomes, Mou et al. targeted exon 3 of the beta-catenin gene Ctnnb1
Table 1 The KO-first gene disruption strategy results in conflicting phenotypes in homozygous
mutant mice
Mice generated using KO-first strategy Homozygous viable Homozygous subviable Homozygous lethal
Bbox1* em1 tm1b
Caskin1 em1 tm1b
Cpsf3* tm1b tm1a
Dbn1* em1 tm1b tm1b
Dnmt3a* tm1a tm1b
Dppa1 tm1a tm1b
Exoc3l2 tm1a tm1b
Foxj3* tm1a tm1b
Ino80 tm1b tm1a
Itm2c* em2 tm1b
Kdm8* tm1a tm1b
Lmna* tm1a tm1b
Nxn* tm1a tm1b
Rundc1* tm1b tm1a
Slc20a2* tm1a tm1b
Tox3* em1 tm1b
Zranb1 tm1a tm1b
Analysis of 427 conditional-ready mouse strains generated using the KO-first strategy reveals that at least 4% of mouse
strains show conflicting phenotypes. *Notably, 12 of 17 lethal/subviable genes express incomplete protein-coding
sequences that could generate truncated proteins to potentially skew the phenotype of homozygous mutant mice
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in a cell line, which induced indels as expected. However, unexpected splicing together
of exons 2 and 4, or of exons 2 and 5, resulted in novel protein isoforms [30]. Immuno-
blotting with beta-catenin specific antibody revealed the presence of mutant proteins
lacking exon 3-encoded amino acid residues, suggesting that indels induced by CRIS
PR/Cas9-sgRNAs can lead to skipping of edited exons, forcing production of truncated
proteins. Makino et al. also found that biallelic on-target frameshift mutations in the
zinc finger protein-encoding gene Gli3 did not result in homozygous-null alleles, and
owing to illegitimate translation, GLI3 protein expression persisted in mouse NIH3T3
cells [14]. More recently, Kapahnke et al. reported that editing of the flotillin-1 gene
(FLOT1) in HeLa cells resulted in translation of an aberrant protein with a dominant
negative effect due to alternative splicing [31]. A more comprehensive analysis of re-
sidual protein expression in HAP1 cells following CRISPR/Cas9-induced frameshift
mutations by Smits and colleagues further supports the observation that truncated pro-
teins can be generated by frameshift mutations by either skipping of the edited exon or
translation reinitiation [15]. Nevertheless, there have been no reports demonstrating
the physiological significance of truncated protein isoforms generated by mutant
mRNA transcripts to date.
Given the possibility that conflicting data with respect to phenotype can result from
differences in the outcomes of different gene-targeting methods [1, 18], we comprehen-
sively characterized Rhbdf1 mutant alleles generated by distinct gene-targeting strat-
egies—definitive-null, CRISPR/Cas9, and targeted KO-first. Initiating with Exome-Seq,
our workflow involved RT-PCR, RNA-Seq, 5′ RACE-PCR, heterologous expression of
tagged expression vectors in 293T cells, and functional rescue assays. We find that
whereas complete loss of exons in Rhbdf1null/null mice causes growth retardation, brain
and heart defects, and death of the majority of mice by P14, CRISPR/Cas9 Rhbdf1v/v
mice, lacking the start codon, and targeted KO-first Rhbdf1v2/v2 mice, lacking exons 4
through 11, do not display growth retardation or any other pathologies observed in
Rhbdf1null/null mice. Additionally, based on our previous findings showing that N-
terminally truncated RHBDF2 causes a gain-of-function phenotype [20], and our data
here showing that the Rhbdf1v/v allele rescues the subviability of Rhbdf1null/null
Rhbdf2−/− mice, causing a wavy hair coat phenotype and inducing enhanced stimulated
secretion of AREG in both Rhbdf1+/+ and Rhbdf1−/− MEFs, we suggest that Rhbdf1v/v
and Rhbdf1v2/v2 mutant mice generate residual mRNA transcripts and protein isoforms
and are gain-of-function mutations. These data also indicate that targeted KO-first al-
leles can generate gain-of-function alleles that rescue the severe phenotype caused by
the null alleles (Additional file 1: Figure S14).
Moreover, our observation that genes can skip exons with stop codons to reinitiate
transcription in vivo to potentially rescue biological activity is in accordance with previ-
ous in vitro studies [14, 15, 29, 30], suggesting the need for deeper analyses of genetic-
ally modified alleles. We propose that in addition to alternative mRNA splicing, other
possible mechanisms that must be accounted for while characterizing mutant mouse
strains include alternative promoter usage and translation initiation from non-AUG
start codons [28, 34–36], both of which can often be assessed by 5′ RACE-PCR, re-
sidual protein analysis by immunoblotting, and functional rescue assays.
Systematic generation and phenotyping of thousands of KO mouse strains by the
IMPC is one of the most significant biological resources available to researchers for
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understanding mammalian gene function [37]. Despite advances in CRISPR-Cas
genome editing technologies, generating conditional KOs is rather challenging
[38], and furthermore, targeted KO-first alleles offer a unique advantage by facili-
tating monitoring of gene function in a tissue- and temporal-specific manner.
Nevertheless, the present study emphasizes that nature can circumvent gene-
targeting strategies to affect the phenotype of homozygous mutant mice. How-
ever, careful selection of gene-targeted ES clones and subsequent residual mRNA
and protein analysis can considerably improve the likelihood of generating mice
harboring conditional or loss-of-function alleles with pertinent phenotypes. More-
over, our data demonstrating that exon skipping in Rhbdf1v/v mice prevents the
multi-organ pathology observed in RHBDF1-deficient mice and rescues embryonic
lethality in RHBDF1:RHBDF2 double deficiency, indicates that the limitation of
targeted KO-first and CRISPR/Cas9 approaches may provide opportunities to
generate gain-of-function alleles that can either provide a partial function of a le-
thal gene to enable further examination of its phenotype in detail, or that can po-
tentially be harnessed for therapeutic benefits in humans.
Methods
Mice
B6N(Cg)-Rhbdf1tm1.1(KOMP)Vlcg/J mice, stock number 026424, were obtained from
The Jackson Laboratory (JAX) Repository and were bred and maintained in a bar-
rier facility at JAX with a 12-h light to 12-h dark cycle. Intercrossing heterozygotes
generated Rhbdf1−/− mice. For generating the viable mice (Rhbdf1v/v), fertilized oo-
cytes from C57BL/6J mice (stock #664) were microinjected using two sgRNAs tar-
geting intron 1–2 and intron 3–4, respectively. Each sgRNA was delivered at a
concentration of 50 ng/μl, along with Cas9 mRNA (Trilink) at 100 ng/μl and Cas9
protein (PNABio) at 30 ng/μl. The microinjection reagents were combined in
nuclease-free T10E0.1 pH 7.5 (Integrated DNA Technologies; Tris 10 mM, EDTA
0.1 mM) supplemented with Rnasin (Promega) at 0.2 U/μl. The sgRNAs were both
designed as TRU guides [39] with 18 nt of target-specific sequence and utilized the
backbone modifications described by Chen et al. [40]. The two guide target sites
are shown here with PAM in parentheses: 5′-GGAGGATCTGTGGAGTTC(agg)
and 5′-GAATCCCTGTTAGGTACC(agg). A total of 128 embryos were microin-
jected and transferred into 6 pseudopregnant females. One transfer failed to deliver
any liveborn pups, but 31 mice (16F/13M) were born from the 107 embryos that
were successfully transferred (29% survival). Nine of 31 (29%) pups showed a drop-
out allele (large deletion of the intervening sequence between the two cut sites).
Genomic DNA from tails was amplified using PCR and then sequenced confirmed by
Sanger sequencing. To validate germline transmission, mice harboring a 569-bp dropout
were backcrossed to C57BL/6J mice and the resulting N1 offspring were intercrossed to
generate the Rhbdf1v/v homozygous mutant mice. Intercrossing Rhbdf1+/− with Rhbdf2−/−
mice generated Rhbdf1−/ -Rhbdf2−/− double homozygous-null pups, and intercrossing
Rhbdf1v/v with Rhbdf2−/−mice generated Rhbdf1v/vRhbdf2−/− double homozygous-null mice.
Generation of Rhbdf2−/− mice has been described previously [20]. Mice were provided food
pellets (Purina LabDiet 5K52; 6% fat, autoclaved) and acidified water ad libitum.
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Histology
Mice euthanized by CO2 asphyxiation were gently perfused through intracardiac injec-
tion of PBS followed by injection of 4% paraformaldehyde. Tissues were fixed overnight
by immersion in 10% neutral buffered formalin and then transferred to 70% ethanol.
Tissue sections were stained with either hematoxylin and eosin (H&E) or Masson’s tri-
chrome stain.
5′ RACE
The SMARTer RACE 5′/3′ Kit was used for performing 5′-rapid amplification of
cDNA ends (RACE) using total RNA according to the manufacturer’s instructions. The
integrity of total RNA isolated from spleen tissues was assessed using the Eppendorf
BioSpectrometer. Total RNA (1 μg) was converted into RACE-Ready first-strand cDNA
and was diluted with 10 μl of Tricine-EDTA. A 28-bp gene-specific primer (see Add-
itional file 1: Figure S10) was used in touchdown PCR with 2.5 μl of 5′-RACE-Ready
cDNA as template to generate the full-length cDNA. RACE products were analyzed fol-
lowing agarose gel electrophoresis, gel extraction, In-Fusion cloning, and Sanger
sequencing.
Cell culture
Primary mouse embryonic fibroblasts (MEFs) were isolated from embryos at 13.5 dpc
(days post coitus) as previously described [20] using Liberase DL (Sigma-Aldrich). Cells
were grown in a humidified chamber at 37 °C with 5% CO2. MEFs and 293T cells were
grown in DMEM 10% fetal bovine serum and antibiotic/antimycotic (Thermo Fisher
Scientific). MEFs were plated in 6-well dishes for transient transfection, western blot-
ting, and ELISA. 293T cells obtained from the Viral Vector Core service at JAX were
mycoplasma and MAP tested.
Site-directed mutagenesis and DNA cloning
Mouse expression plasmids containing cDNA encoding Rhbdf1 was obtained from Ori-
Gene. The Q5® Site-Directed Mutagenesis Kit was used to introduce site-specific muta-
tions in the mouse Rhbdf1 plasmid according to the manufacturer’s instructions and
confirmed by Sanger sequencing. Primers were designed using the NEBaseChanger tool
for site-directed substitutions and deletions, and purchased from IDT.
Genotyping
Two-millimeter tail tips were incubated overnight in lysis buffer containing Proteinase
K at 55 °C in a shaker incubator and denatured at 95 °C for 5 min. One microliter of
undiluted DNA was used for 25 μl PCR reaction. For genotyping primers and proto-
cols, see Additional file 1: Figure S15.
Reverse transcriptase PCR (RT-PCR)
The Maxima First Strand cDNA Synthesis Kit (Thermo Fisher Scientific) was used for
cDNA synthesis from total RNA (1 μg) using oligo(dT)18 primers. Reaction tubes con-
taining either no reverse transcriptase or no template served as negative controls.
cDNA synthesis was performed according to the manufacturer’s instructions.
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SYBR Green real-time PCR
PowerUp SYBR Green Master Mix was used for running the real-time PCR (Thermo
Fisher Scientific). For a 10 μl/well PCR reaction, 100 ng of cDNA, 800 nM exon 16 for-
ward primer (CCTCCTGCCTTTCCTCAATC), 800 nM exon 17 reverse primer
(GAAGATGGCACTGGCTAGATT), and 5 μl of 2X master mix were mixed together
and PCR was run on a ViiA 7 Real-Time PCR System using the standard cycling mode
(primer Tm ≥ 60 °C).
Immunoblotting
293T cells seeded in six-well dishes and transiently transfected with expression plas-
mids were treated with 300 μl of RIPA lysis buffer (Cell Signaling Technology) and in-
cubated on ice for 30 min. Cells were then centrifuged at 13,000×g at 4 °C for 10 min,
20 μg of total cell lysate was loaded in 4–20% Tris-Glycine Mini Gels, and samples were
allowed to migrate for 90 min. Proteins were transferred onto a PVDF membrane using
the iBlot™ Gel Transfer device, and membranes were blocked with 5% milk for 1 h at
room temperature and exposed to either FLAG-specific (Origene, #TA50011) or actin
(Cell Signaling Technology, #4970) antibodies overnight at 4 °C. Membranes were then
washed and exposed to anti-mouse and anti-rabbit secondary antibodies, respectively,
before visualizing the blots using a G:BOX gel documentation system (Syngene, Fred-
erick, USA).
DNA isolation and exome sequencing
DNA was isolated from spleen using the Wizard Genomic DNA Purification Kit (Pro-
mega) according to the manufacturer’s protocols. DNA quality was assessed using a
Genomic DNA Screen Tape (Agilent Technologies) and Nanodrop 2000 spectropho-
tometer (Thermo Scientific). DNA concentration was assessed using a Qubit dsDNA
BR Assay Kit (Thermo Scientific). The library was prepared by the Genome Technolo-
gies core facility at JAX using Kapa Hyper Prep (Roche Sequencing and Life Science)
and SureSelectXT Mouse All Exon V2 Target Enrichment System (Agilent Technolo-
gies), according to the manufacturer’s instructions. Briefly, the protocol entails shearing
the DNA using the Covaris E220 Focused-ultrasonicator (Covaris), ligating Illumina-
specific adapters, and PCR amplification. The amplified DNA library is then hybridized
to Mouse All Exon probes, amplified using indexed primers, and checked for quality
and concentration using High Sensitivity D5000 Screen Tape (Agilent Technologies)
and quantitative PCR (KAPA Biosystems), according to the manufacturers’ instructions.
The library was sequenced 100-bp paired-end on the HiSeq 4000 (Illumina) using
HiSeq 3000/4000 SBS Kit reagents (Illumina). Sequenced reads were filtered and
trimmed for quality scores > 30 using a custom python script. Filtered Exome-Seq reads
were aligned to Mus musculus GRCm38 using BWA-mem (0.7.9a-r786). Bam files were
processed as needed (e.g., sorting, deduplication) with Picard/GATK (3.4–0).
RNA isolation and sequencing
RNA was isolated from spleen using the MagMAX mirVana Total RNA Isolation Kit
(Thermo Fisher) and the KingFisher Flex purification system (Thermo Fisher). The tis-
sue was lysed and homogenized in TRIzol Reagent (Thermo Fisher). After the addition
Hosur et al. Genome Biology          (2020) 21:168 Page 20 of 25
of chloroform, the RNA-containing aqueous layer was removed for RNA isolation ac-
cording to the manufacturer’s protocol, beginning with the RNA bead binding step.
RNA concentration and quality were assessed using the Nanodrop 2000 spectropho-
tometer (Thermo Scientific) and the RNA Total RNA Nano assay (Agilent Technolo-
gies). The library was prepared by the Genome Technologies core facility at JAX using
the KAPA mRNA HyperPrep Kit (KAPA Biosystems), according to the manufacturer’s
instructions. Briefly, the protocol entails isolation of polyA containing mRNA using
oligo-dT magnetic beads, RNA fragmentation, first- and second-strand cDNA synthe-
sis, ligation of Illumina-specific adapters containing a unique barcode sequence for each
library, and PCR amplification. The library was checked for quality and concentration
using the D5000 Screen Tape (Agilent Technologies) and quantitative PCR (KAPA Bio-
systems), according to the manufacturers’ instructions. The library was sequenced 100
bp paired-end on the HiSeq 4000 (Illumina) using HiSeq 3000/4000 SBS Kit reagents
(Illumina). Filtered RNA-Seq reads were aligned to Mus musculus GRCm38 using Bow-
tie2 (v2.2.0).
AREG ELISA
MEFs cultured in collagen-coated six-well plates were transiently transfected with indi-
cated expression vectors and stimulated overnight with 100 nM PMA (R&D Systems,
Minneapolis, USA). Cell culture supernatant was centrifuged at 2500×g at 4 °C for 5
min and 100 μl of supernatant was used to measure AREG protein levels by a Mouse
Amphiregulin DuoSet ELISA Developmental Kit (#DY989, R&DSystems).
Incomplete human and mouse protein-coding sequences
Data were accessed from Ensembl via the SQL databases (useastdb.ensembl.org; user
anonymous) [24]. The databases homo_sapiens_core_99_38 and mus_musculus_core_
99_38 were queried for all transcripts where the attribute type was cds_start_NF(CDS
start not found) or cds_end_NF (CDS end not found). Transcript IDs were used to se-
lect for gene ids, Ensembl stable gene ids, and biotypes assigned to transcripts and
genes. Ensembl gene ids were used to select gene symbols via Ensembl Biomart. Data
were collected in Microsoft Excel, and functions of Excel were used to combine
(VLOOKUP) and filter the datatypes. We have developed a web application (https://
incompletecds.jax.org) to identify protein-coding genes that could be predisposed to
targeted KO-first- and CRISPR/Cas9-mediated unexpected transcription and
translation.
Statistical analysis
Prism v7 software (GraphPad) was used to generate the Kaplan–Meier survival curves.
Student’s t test was used to determine whether there was a statistically significant dif-
ference between two groups. P < 0.05 was considered to be statistically significant.
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Additional file 1: Figure S1. Gene-targeting strategies for generating null or conditional mutant alleles: a. In the
definitive-null design, the complete coding sequence of a gene is flanked by two loxP sites, and recombination
with a cre recombinase excises the floxed gene segment, creating LacZ-tagged null alleles. Loss of the complete
Hosur et al. Genome Biology          (2020) 21:168 Page 21 of 25
coding sequence of the target gene ensures homozygous-null alleles. b. Targeted KO-first alleles harbor FRT sites
flanking “LacZ and a neo gene,” and also harbor loxP sites flanking either an exon (exon 2, left) or specific exons
chosen to be excised (exons 4 through 11, right, in this case), permitting recombination with Flp or cre recombi-
nases and enabling conditional mutagenesis. Application of cre recombinase deletes exons flanked by two loxP
sites, generating LacZ-tagged null alleles (tm1b). Application of Flp recombinase to this allele is described in the le-
gend for 1C. c. Application of Flp recombinase to targeted KO-first alleles reverts the knockout-first alleles into
conditional-ready alleles by excising lacZ and a neo gene. Subsequent recombination of conditional-ready alleles
with cre recombinase generates conditional mutant alleles (tm1d). Figure S2. Sub-viability in Rhbdf1-/- Rhbdf2-/-
double mutant mice (A6): a. Breeding strategy and the number of mice generated and genotyped by PCR b & c.
Rhbdf1-/-Rhbdf2-/- double mutant mice displayed “eyelids open at birth” phenotype (arrows) in mouse embryos har-
vested on embryonic day 15 (e15.5) (B) and in pups at day 2 (C). No defects were observed in Rhbdf1+/-Rhbdf2-/- lit-
termates. Figure S3. PCR and genotyping of Rhbdf1v/v allele: Schematic showing the TRU-guides (sgRNAs 2256
and 2257) used to excise exons 2 and 3 in the Rhbdf1 gene. Also shown are the PCR primers and Taq DNA Poly-
merase thermocycling conditions used to genotype Rhbdf1v/v mice (A7). PCR products were sequenced to verify
the 569-bp deletion. Figure S4. Histology and 5’ RACE products of Rhbdf1v/v allele: a. H&E sections of Rhbdf1v/v
mice displaying no abnormalities in the heart, brain, truncal skin sections, kidney, spleen, and liver tissues. b. Sche-
matic representation of Rhbdf1v/v transcript variant with a different transcription start site. 5’ RACE identified an al-
ternative exon (highlighted in light orange) that splices with exon 4 to reinitiate transcription from a different start
site in exon 4, as opposed to using the conventional start site in exon 2. Notably, splicing of alternative exon with
exon 4 is also observed in other Rhbdf1 predicted transcript variants X1, X2, X3, X4, X9, and X14. Figure S5. Stimu-
lated secretion of AREG: Stimulated secretion of AREG in Rhbdf1+/+ and Rhbdf1-/- primary MEFs, passage one, after
overnight stimulation with 100 nM PMA. Following stimulation, cell-culture supernatants were analyzed using a
mouse AREG ELISA kit. Data represent mean ± S.D; ***p<0.001. Figure S6. CRISPR/Cas9 Rhbdf1v/v allele (A7) re-
verses sub-viability in Rhbdf1-/- Rhbdf2-/- double mutant mice: a. Images of representative postnatal day 21 Rhbdf1v/+
Rhbdf2-/- mice (left) and Rhbdf1v/v Rhbdf2-/- mice (right). Notably, Rhbdf1v/v Rhbdf2-/- mice develop a wavy hair coat
(arrow). b. H&E-stained sections of skin from adult Rhbdf1v/+ Rhbdf2-/- and Rhbdf1v/v Rhbdf2-/- mice. The Rhbdf1v/v
Rhbdf2-/- skin displays follicular dystrophy (arrow), hyperplasia (*), and hyperkeratosis (arrowhead), whereas that of
Rhbdf1v/+ Rhbdf2-/- mice does not display these phenotypes. Top panels: low magnification; bottom panels: high
magnification. c. Rhbdf1v/v Rhbdf2-/- double mutant mice displayed an “eyelids open at birth” phenotype in 3-day-
old mouse pups (arrow). No such defects were observed in Rhbdf1v/+ Rhbdf2-/- mice. Top panels: low magnification;
bottom panels: high magnification. d. No cardiac or brain abnormalities were observed in either Rhbdf1v/v Rhbdf2-/-
double mutant mice or Rhbdf1v/+ Rhbdf2-/- mice. Figure S7. Non-AUG protein coding transcripts of Rhbdf1: a.
Mouse non-AUG protein-coding Rhbdf1 transcript (Top). Human non-AUG protein-coding RHBDF1 transcript. b. C-
terminal Myc-DDK-tagged empty vector (lanes 1, 2), non-AUG vector (lanes 3, 4) or a positive control vector (798-
bp; lanes 5, 6) were transiently expressed in 293T cells, and cell lysates were analyzed using western blotting with
FLAG-specific antibody. Blots were washed, blocked in 5% nonfat dry milk, and re-probed with anti-actin antibody.
Figure S8. Retention of En2 splice acceptor site in the Rhbdf1v2/v2 allele:a. mRNA expression of the Rhbdf1 gene
assessed by RT-qPCR using SYBR Green RT-PCR master mix and, exon 16 forward and exon 17 reverse primers.
There is no difference in the mRNA levels of Rhbdf1 between Rhbdf1+/+ and Rhbdf1v2/v2 mice. b. Schematic repre-
sentation of Rhbdf1v2/v2 allele indicating the presence of En2 splice acceptor site (Extra) between exons 3 and 12.
RT-PCR of spleens from Rhbdf1v2/v2 mutant mice using primers in exon 3 and exon 12. Exon 3 forward (2817 For)
and exon 12 reverse (2818 Rev) primers generated a 324-bp product, instead of an expected 209-bp product due
to splicing of exons 3 and 12 together. c. Sanger’s sequencing indicated the presence of En2 splice acceptor site
(Extra) flanked by exons 3 and 12. d. Schematic representation of the targeted KO-first allele used to generate ES
cell clones displaying the splice acceptor site downstream of exon 3. e. Transcription and translation from the con-
ventional start site in exon 2 can yield a 10.8 kDa truncated protein owing to a stop codon in the splice acceptor
site. Figure S9. 5’ RACE identifies alternative exon upstream of the conventional exon 1: a. Schematic representa-
tion of the Rhbdf1 KO-first allele used to generate ES cell clones displaying an alternative exon 1 (arrow) upstream
of the conventional exon 1. b. Schematic representation of the Rhbdf1 genomic DNA displaying the alternative
exon 1 (arrow) identified by 5’ RACE. The DNA sequence of the alternative exon 1 is also shown. Figure S10.
Translation initiation from alternative exon 1 in the Rhbdf1v2/v2 allele could generate a truncated protein: a. Sche-
matic representation of an Rhbdf1v2/v2 splice variant displaying transcription initiation from the alternative exon 1,
which could result in a 285-bp transcript and a 12.3 kDa truncated protein. b. Primers (2827, 2818, and 2826) used
to sequence verify splicing of alternative exon 1 with exon 2 (top), and En2 splice acceptor site (En2 SA) with exon
12 (bottom). Figure S11. Splicing of alternative exon 1 with exon 4 generates an N-terminally truncated variant 1
protein: a. Schematic representation of an Rhbdf1v2/v2 splice variant displaying transcription initiation from the exon
14, which could result in a 801-bp transcript and a 32.77 kDa N-terminally truncated protein (variant 1). b. RT-PCR
of spleens from Rhbdf1v2/v2 mutant mice using primers (2827 and 2814) in alternative exon 1 and exon 15 resulted
in a 430-bp amplicon. Sanger’s sequence demonstrated splicing of alternative exon 1 with En2 SA. Notably,
Rhbdf1v/v mutant mice resulted in an amplicon with primers 2827 and 2814, suggesting the use of alternative exon
1. However, higher molecular weight PCR fragments in Rhbdf1v/v mutant mice can be attributed to the presence of
exons 4 through 11, which are excised in Rhbdf1v2/v2 mutant mice. Thermocycling conditions using Taq DNA Poly-
merase with standard buffer are also shown. Figure S12. Splicing of alternative exon 1 with exon 4 can also gen-
erate an N-terminally truncated variant 2 protein: a. Schematic representation of an Rhbdf1v2/v2 splice variant
displaying transcription initiation from the exon 15, which could result in a 717-bp splice variant and a 29.6 kDa N-
terminally truncated protein (variant 2). b. RT-PCR of spleens from Rhbdf1v2/v2 mutant mice using primers (2827 and
2814) in alternative exon 1 and exon 15 also resulted in a 639-bp amplicon. Sanger’s sequence demonstrated spli-
cing of En2 SA with exon 12. Figure S13. Double digests with NEB's restriction enzymes: Double digests of C-
terminal Myc-DDK-tagged vectors (1 μg DNA) with NEB's restriction enzymes EcoRI-HF and NotI-HF. Figure S14.
Unpredicted reinitiation of transcription and translation: Our data strongly suggests that mice harboring
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homozygous definitive-null or homozygous targeted KO-first alleles are homozygous null, however, mice harboring
homozygous KO-first mutant alleles tm1b and tm1d can be null or gain-of-function or hypomorphic mice (arrows)
owing to unpredicted reinitiation of transcription and translation. Figure S15. PCR and genotyping of Rhbdf1 and
Rhbdf2 KOMP alleles: a. PCR primers used to genotype Rhbdf1-/- mice (A5) generated in the present study. Thermo-
cycling conditions using Taq DNA Polymerase with standard buffer. b. Schematic showing the PCR strategy and
the primers used to genotype Rhbdf2-/- mice. Thermocycling conditions using Taq DNA Polymerase with standard
buffer. PCR products were purified and sequence verified.
Additional file 2. Table S1. Incomplete CDS mouse transcripts.
Additional file 3. Table S2. Incomplete CDS mouse genes.
Additional file 4. Table S3. Incomplete CDS human transcripts.
Additional file 5. Table S4. Incomplete CDS human genes.
Additional file 6. Table S5. Genes retaining residual protein expression upon CRISPR/Cas9-induced indels.
Additional file 7. Table S6. Bioinformatic analyses of conditional-ready, lethal, and subviable strains.
Additional file 8. Table S7. Bioinformatic analyses of targeted KO-first strains exhibiting conflicting phenotypes.
Additional file 9. Review history.
Acknowledgements
We gratefully acknowledge the contributions of the JAX core for expert assistance with the work described in this
publication, especially Mary Barter, Chrystal Snow, Christina Petros, and Heidi Munger at the Genome Technologies,
Peter Kutny and Bill Buaas at Genetic Engineering Technologies, Gregg TeHennepe at Computational Sciences, and
Nick Gott and Elaine Bechtel at Histopathology and Microscopy Sciences. We thank Dr. Carl P. Blobel for providing
frozen spleens from the Rhbdf1v2/v2 mice and for critically reading the manuscript. We thank the members of the
Rosenthal laboratory (Drs. Mauro Costa and Milena Furtado) at JAX for technical support and for helpful suggestions.
We thank Michelle L. Farley, Cindy Avery, and Todd Nason for maintenance of mouse colonies and for monitoring of
early pup survival, and the “eyelids open at birth” phenotype. We thank Lihong Zhao, Rosalinda A. Doty, Richard S.
Maser, and Ryuta Ishimura for helpful discussion, and Stephen B. Sampson for critical reading of the manuscript. We
also thank Zoe Reifsnyder in preparing illustrations for the manuscript.
Peer review information
Yixin Yao was the primary editor on this article and managed its editorial process and peer review in collaboration
with the rest of the editorial team.
Review history
The review history is available as Additional file 9.
Authors’ contributions
VH, LDS, and MVW designed and supervised the project. VH, BEL, and DL performed the experiments. GAC and VK
contributed to bioinformatic analyses. VH, LDS, and MVW analyzed the data and wrote the manuscript. All authors
critically reviewed and approved the manuscript.
Funding
This work was supported in part by the National Institutes of Health under Award Number P30CA034196, R21
OD027052 (VH, MW), ODO26440 (LS), AI132963 (LS), and the Director’s Innovation Fund at JAX (VH, MW).
Availability of data and materials
All data generated or analyzed during this study are included in this published article and its supplementary
information files. Exome-seq and RNA-seq data are available under the NCBI BioProject: PRJNA641484 [41].
Ethics approval and consent to participate
The Animal Care and Use Committee (Animal Use Summary # 11006) at The Jackson Laboratory approved all
experimental procedures.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1The Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, USA. 2Arthritis and Tissue Degeneration Program,
Hospital for Special Surgery at Weill Cornell Medicine, New York, NY 10021, USA.
Received: 15 April 2020 Accepted: 29 June 2020
References
1. Christova Y, Adrain C, Bambrough P, Ibrahim A, Freeman M. Mammalian iRhoms have distinct physiological functions
including an essential role in TACE regulation. EMBO Rep. 2013;14:884–90.
Hosur et al. Genome Biology          (2020) 21:168 Page 23 of 25
2. Issuree PD, Maretzky T, McIlwain DR, Monette S, Qing X, Lang PA, Swendeman SL, Park-Min KH, Binder N, Kalliolias GD,
et al. iRHOM2 is a critical pathogenic mediator of inflammatory arthritis. J Clin Invest. 2013;123:928–32.
3. Yan Z, Zou H, Tian F, Grandis JR, Mixson AJ, Lu PY, Li LY. Human rhomboid family-1 gene silencing causes apoptosis or
autophagy to epithelial cancer cells and inhibits xenograft tumor growth. Mol Cancer Ther. 2008;7:1355–64.
4. Zhou Z, Liu F, Zhang ZS, Shu F, Zheng Y, Fu L, Li LY. Human rhomboid family-1 suppresses oxygen-independent
degradation of hypoxia-inducible factor-1alpha in breast cancer. Cancer Res. 2014;74:2719–30.
5. Xu Q, Chen C, Liu B, Lin Y, Zheng P, Zhou D, Xie Y, Lin Y, Guo C, Liu J, Li L. Association of iRhom1 and iRhom2
expression with prognosis in patients with cervical cancer and possible signaling pathways. Oncol Rep. 2020;43:41–54.
6. Austin CP, Battey JF, Bradley A, Bucan M, Capecchi M, Collins FS, Dove WF, Duyk G, Dymecki S, Eppig JT, et al. The
knockout mouse project. Nat Genet. 2004;36:921–4.
7. Brown SD, Moore MW. Towards an encyclopaedia of mammalian gene function: the International Mouse Phenotyping
Consortium. Dis Model Mech. 2012;5:289–92.
8. Collins FS, Finnell RH, Rossant J, Wurst W. A new partner for the international knockout mouse consortium. Cell. 2007;
129:235.
9. Bradley A, Anastassiadis K, Ayadi A, Battey JF, Bell C, Birling MC, Bottomley J, Brown SD, Burger A, Bult CJ, et al. the
mammalian gene function resource: the International Knockout Mouse Consortium. Mamm Genome. 2012;23:580–6.
10. Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, Iyer V, Mujica AO, Thomas M, Harrow J, Cox T, et al. A
conditional knockout resource for the genome-wide study of mouse gene function. Nature. 2011;474:337–42.
11. White JK, Gerdin AK, Karp NA, Ryder E, Buljan M, Bussell JN, Salisbury J, Clare S, Ingham NJ, Podrini C, et al. Genome-wide
generation and systematic phenotyping of knockout mice reveals new roles for many genes. Cell. 2013;154:452–64.
12. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R. One-step generation of mice carrying
mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013;153:910–8.
13. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA
endonuclease in adaptive bacterial immunity. Science. 2012;337:816–21.
14. Makino S, Fukumura R, Gondo Y. Illegitimate translation causes unexpected gene expression from on-target out-of-
frame alleles created by CRISPR-Cas9. Sci Rep. 2016;6:39608.
15. Smits AH, Ziebell F, Joberty G, Zinn N, Mueller WF, Clauder-Munster S, Eberhard D, Falth Savitski M, Grandi P, Jakob P,
et al. Biological plasticity rescues target activity in CRISPR knock outs. Nat Methods. 2019;16:1087–93.
16. Tuladhar R, Yeu Y, Tyler Piazza J, Tan Z, Rene Clemenceau J, Wu X, Barrett Q, Herbert J, Mathews DH, Kim J, et al. CRIS
PR-Cas9-based mutagenesis frequently provokes on-target mRNA misregulation. Nat Commun. 2019;10:4056.
17. Anderson JL, Mulligan TS, Shen MC, Wang H, Scahill CM, Tan FJ, Du SJ, Busch-Nentwich EM, Farber SA. mRNA
processing in mutant zebrafish lines generated by chemical and CRISPR-mediated mutagenesis produces unexpected
transcripts that escape nonsense-mediated decay. PLoS Genet. 2017;13:e1007105.
18. Li X, Maretzky T, Weskamp G, Monette S, Qing X, Issuree PD, Crawford HC, McIlwain DR, Mak TW, Salmon JE, Blobel CP.
iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling. Proc Natl Acad Sci U S A.
2015;112:6080–5.
19. Adrain C, Zettl M, Christova Y, Taylor N, Freeman M. Tumor necrosis factor signaling requires iRhom2 to promote
trafficking and activation of TACE. Science. 2012;335:225–8.
20. Hosur V, Johnson KR, Burzenski LM, Stearns TM, Maser RS, Shultz LD. Rhbdf2 mutations increase its protein stability and
drive EGFR hyperactivation through enhanced secretion of amphiregulin. Proc Natl Acad Sci U S A. 2014;111:E2200–9.
21. McIlwain DR, Lang PA, Maretzky T, Hamada K, Ohishi K, Maney SK, Berger T, Murthy A, Duncan G, Xu HC, et al. iRhom2
regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science. 2012;335:229–32.
22. Du X, Tabeta K, Hoebe K, Liu H, Mann N, Mudd S, Crozat K, Sovath S, Gong X, Beutler B. Velvet, a dominant Egfr
mutation that causes wavy hair and defective eyelid development in mice. Genetics. 2004;166:331–40.
23. Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol. 2005;6:32–43.
24. Cunningham F, Achuthan P, Akanni W, Allen J, Amode MR, Armean IM, Bennett R, Bhai J, Billis K, Boddu S, et al.
Ensembl 2019. Nucleic Acids Res. 2019;47:D745–d751.
25. Kozak M. Context effects and inefficient initiation at non-AUG codons in eucaryotic cell-free translation systems. Mol Cell
Biol. 1989;9:5073–80.
26. Gordon K, Futterer J, Hohn T. Efficient initiation of translation at non-AUG triplets in plant cells. Plant J. 1992;2:809–13.
27. Peabody DS. Translation initiation at non-AUG triplets in mammalian cells. J Biol Chem. 1989;264:5031–5.
28. Diaz de Arce AJ, Noderer WL, Wang CL. Complete motif analysis of sequence requirements for translation initiation at
non-AUG start codons. Nucleic Acids Res. 2018;46:985–94.
29. Lalonde S, Stone OA, Lessard S, Lavertu A, Desjardins J, Beaudoin M, Rivas M, Stainier DYR, Lettre G. Frameshift indels
introduced by genome editing can lead to in-frame exon skipping. PLoS One. 2017;12:e0178700.
30. Mou H, Smith JL, Peng L, Yin H, Moore J, Zhang XO, Song CQ, Sheel A, Wu Q, Ozata DM, et al. CRISPR/Cas9-mediated
genome editing induces exon skipping by alternative splicing or exon deletion. Genome Biol. 2017;18:108.
31. Marcel Kapahnke, Antje Banning, Ritva Tikkanen. Random Splicing of Several Exons Caused by a Single Base Change in
the Target Exon of CRISPR/Cas9 Mediated Gene Knockout. Cells. 2016;5(4):45.
32. Birling M-C, Yoshiki A, Adams DJ, Ayabe S, Beaudet AL, Bottomley J, Bradley A, Brown SD, Bürger A, Bushell W, et al. A
resource of targeted mutant mouse lines for 5,061 genes. bioRxiv. 2019:844092.
33. Dickinson ME, Flenniken AM, Ji X, Teboul L, Wong MD, White JK, Meehan TF, Weninger WJ, Westerberg H, Adissu H,
et al. High-throughput discovery of novel developmental phenotypes. Nature. 2016;537:508–14.
34. Kochetov AV. Alternative translation start sites and hidden coding potential of eukaryotic mRNAs. Bioessays. 2008;30:683–91.
35. Huin V, Buee L, Behal H, Labreuche J, Sablonniere B, Dhaenens CM. Alternative promoter usage generates novel shorter
MAPT mRNA transcripts in Alzheimer's disease and progressive supranuclear palsy brains. Sci Rep. 2017;7:12589.
36. Kearse MG, Wilusz JE. Non-AUG translation: a new start for protein synthesis in eukaryotes. Genes Dev. 2017;31:1717–31.
37. Dolgin E. Mouse library set to be knockout. Nature. 2011;474:262–3.
38. Gurumurthy CB, O'Brien AR, Quadros RM, Adams J Jr, Alcaide P, Ayabe S, Ballard J, Batra SK, Beauchamp MC, Becker KA,
et al. Reproducibility of CRISPR-Cas9 methods for generation of conditional mouse alleles: a multi-center evaluation.
Genome Biol. 2019;20:171.
Hosur et al. Genome Biology          (2020) 21:168 Page 24 of 25
39. Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs.
Nat Biotechnol. 2014;32:279–84.
40. Chen B, Gilbert LA, Cimini BA, Schnitzbauer J, Zhang W, Li GW, Park J, Blackburn EH, Weissman JS, Qi LS, Huang B.
Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell. 2013;155:1479–91.
41. Hosur V, Low BE, Li D, Stafford GA, Kohar V, Shultz LD, Wiles MV: Genes adapt to outsmart gene targeting strategies in
mutant mouse strains by skipping exons to reinitiate transcription and translation. Dataset. National Center for
Biotechnology Information: PRJNA641484 2020.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Hosur et al. Genome Biology          (2020) 21:168 Page 25 of 25
